Investing.com - Amoy Diagnostics reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Amoy Diagnostics announced earnings per share of ¥0.35 on revenue of ¥206.80. Analysts polled by Investing.com anticipated EPS of ¥0.20 on revenue of ¥282.55M.
Amoy Diagnostics shares are up 50% from the beginning of the year , still down 54.65% from its 52 week high of ¥48.88 set on Monday, November 29, 2021.
Amoy Diagnostics shares lost 11.50% in intra-day trade the report.
Amoy Diagnostics follows other major Healthcare sector earnings this month
Amoy Diagnostics's report follows an earnings missed by Walvax BioTech on Tuesday, who reported EPS of ¥0.07 on revenue of ¥1.36B, compared to forecasts EPS of ¥0.18 on revenue of ¥1.55B.
Top Choice Medical Investment had missed expectations on Tuesday with third quarter EPS of ¥0.68 on revenue of ¥821.2M, compared to forecast for EPS of ¥0.95 on revenue of ¥1.08B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar